Pregled bibliografske jedinice broj: 394071
Serological markers of inflammatory bowel disease
Serological markers of inflammatory bowel disease // Biochemia Medica, 23 (2013), 1; 28-42 doi:10.11613/BM.2013.006 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 394071 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Serological markers of inflammatory bowel disease
Autori
Tešija Kuna, Andrea
Izvornik
Biochemia Medica (1330-0962) 23
(2013), 1;
28-42
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
inflammatory bowel disease; colitis ulcerative; Crohn disease; serological tests
Sažetak
Inflammatory bowel disease (IBD) is a heterogeneous group of chronic inflammatory disorders of the gastrointestinal tract with two main distinguishable entities, Crohn’s disease (CD) and ulcerative colitis (UC). IBD-unclassified (IBD-U) is a diagnosis that covers the “grey” zone of diagnostic uncertainty between UC and CD. Current diagnosis of IBD relies on the clinical, endoscopic, radiological, histological and biochemical features, but this approach has shortcomings especially in cases of overlapping symptoms of CD and UC. The need for a diagnostic tool that would improve the conventional methods in IBD diagnosis directed the search towards potential immunological markers, since an aberrant immune response against microbial or endogenous antigens in a genetically susceptible host seems to be implicated in IBD pathogenesis. The spectrum of antibodies to different microbial antigens and autoantibodies associated with IBD is rapidly expanding. Most of these antibodies are associated with CD like anti-glycan antibodies: anti-Saccharomices cerevisiae (ASCA) and the recently described anti-laminaribioside (ALCA), anti-chitobioside (ACCA), anti-mannobioside (AMCA), anti-laminarin (anti-L) and anti-chitin (anti-C) antibodies ; in addition to other antibodies that target microbial antigens: anti-outer membrane porin C (anti-OmpC), anti-Cbir1 flagellin and anti-I2 antibody. Also, autoantibodies targeting the exocrine pancreas (PAB) were shown to be highly specific for CD. In contrast, UC has been associated with anti-neutrophil cytoplasmic autoantibodies (pANCA) and antibodies against goblet cells (GAB). Current evidence suggests that serologic panels of multiple antibodies are useful in differential diagnosis of CD versus UC and can be a valuable aid in stratifying patients according to disease phenotype and risk of complications.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Projekti:
134-0061245-0205 - Hemoreološki poremećaji u kroničnim bolestima (Vrkić, Nada, MZOS ) ( CroRIS)
134-1340227-0200 - Upala i udio farmakogenetike u razvoju i ishodu akutnih i kroničnih bolesti (Šimundić, Ana-Maria, MZOS ) ( CroRIS)
Ustanove:
KBC "Sestre Milosrdnice"
Poveznice na cjeloviti tekst rada:
Pristup cjelovitom tekstu rada doi www.biochemia-medica.com dx.doi.orgCitiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- CA Search (Chemical Abstracts)
- EMBASE (Excerpta Medica)
- MEDLINE
- Scopus
- SCIE
- ABSCO
- Chemical Abstracts Service (CAS)